Evangelia Lydaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Evangelia Lydaki has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Anthi Gafou
Transfusion Service of GONK Oi Agioi Anargyroi Hospital Athens Greece
1 shared publication - Dinara Samarkanova
Banc de Sang i Teixits Barcelona Spain
1 shared publication - Gabriele Scimemi
Transfusion Medicine Ospedale S. Antonio Abate Trapani Italy
1 shared publication - Javier Calvo
Banc de Sang i Teixits de les Illes Balears, Cell Therapy and Tissue Engineering Group (TERCIT), Balearic Islands Health Research Institut (IdISBa) Palma Spain
1 shared publication - José Antonio García-Erce
Banco de Sangre y Tejidos de Navarra, Pamplona, Navarra, España; Aragón Health Research Institute (IACS), Aragon Institute for Health Research (IIS Aragon), Zaragoza; Grupo Español de Rehabilitación Multimodal (GERM), Zaragoza, España; Grupo de Investigación Gestión en el Paciente Sangrante-PBM, Instituto de Investigación Sanitaria, Hospital Universitaria La Paz (IdiPAZ), Madrid, España
1 shared publication - Larysa Mykhailova
Transfusion Medicine Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico Milan Italy
1 shared publication
Latest Publications
- Open Access
- 16 February 2025
- Published by Wiley in Vox Sanguinis
- Vol. 120 (5) , 513-516
A procedure using low‐cost reagents to prepare allogeneic platelet gel from standard platelet units
Background and Objectives: Highly effective procedures for the preparation of allogeneic platelet gel (PG) use Ca‐gluconate and batroxobin, an expensive commercial reagent. In this preliminary study, we explored the use of the plasmin‐inhibitor, low‐cost drug tranexamic acid (TXA) in place of batroxobin, based on the literature supporting TXA ability to prevent fibrinolysis and stabilize the gel formed by fibrin polymerization prompted by Ca‐gluconate.Materials and Methods: Eight blood centres determined PG weight and volume of non‐gelled, liquid portion in 116 PG prepared in 20‐mL commercial BioNest D bags. Ten‐millilitre platelet aliquots from platelets in 100% plasma or in 35% plasma/65% platelet additive solution (PAS) were aseptically transferred into the D bag, followed by the injection of 3.3 mL of 10% Ca‐gluconate and 0.4 mL of TXA. After 30‐min incubation, PG weight and non‐gelled liquid volume were determined.Results: PG weight and liquid volume at 30 min were 6.5 ± 3.4 g and 7.4 ± 3.5 mL with platelets in 100% plasma, and 3.7 ± 3.0 g and 10.2 ± 3.3 mL with PAS platelets, respectively.Conclusion: This study provides preliminary evidence supporting the use of TXA as a low‐cost reagent for PG manufacturing from platelets in 100% plasma.
- 16 February 2025
- Published by Wiley in Vox Sanguinis
- Vol. 120 (5) , 513-516
Open AccessA procedure using low‐cost reagents to prepare allogeneic platelet gel from standard platelet units
Background and Objectives: Highly effective procedures for the preparation of allogeneic platelet gel (PG) use Ca‐gluconate and batroxobin, an expensive commercial reagent. In this preliminary study, we explored the use of the plasmin‐inhibitor, low‐cost drug tranexamic acid (TXA) in place of batroxobin, based on the literature supporting TXA ability to prevent fibrinolysis and stabilize the gel formed by fibrin polymerization prompted by Ca‐gluconate.Materials and Methods: Eight blood centres determined PG weight and volume of non‐gelled, liquid portion in 116 PG prepared in 20‐mL commercial BioNest D bags. Ten‐millilitre platelet aliquots from platelets in 100% plasma or in 35% plasma/65% platelet additive solution (PAS) were aseptically transferred into the D bag, followed by the injection of 3.3 mL of 10% Ca‐gluconate and 0.4 mL of TXA. After 30‐min incubation, PG weight and non‐gelled liquid volume were determined.Results: PG weight and liquid volume at 30 min were 6.5 ± 3.4 g and 7.4 ± 3.5 mL with platelets in 100% plasma, and 3.7 ± 3.0 g and 10.2 ± 3.3 mL with PAS platelets, respectively.Conclusion: This study provides preliminary evidence supporting the use of TXA as a low‐cost reagent for PG manufacturing from platelets in 100% plasma.